MT Receptor
Signaling Pathway Map
Research Area
Inhibitory Selectivity
Isoform-specific Inhibitors
MT Receptor Products
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S1259 |
RamelteonRamelteon (TAK-375) is a novel melatonin receptor agonist for human MT1 and MT2 receptors and chick forebrain melatonin receptors with Ki of 14 pM, 112 pM and 23.1 pM, respectively. |
(M) (Left) Cresyl violet and Luxol fast blue staining of ipsilateral corpus striatum on day 3 post-TBI. Scale bar = 50 µm. (Right) Bar graph shows that ramelteon did not increase the percentage of area with normal myelin in the Nrf2 KO mouse brain compared with that in the vehicle group. n = 6 mice/group. *P < 0.05 vs. sham group (one-way ANOVA followed by Bonferroni post hoc test). (N) (Left) Fluoro-Jade C staining of the perilesional cerebral cortex on day 3 post-TBI. Scale bar = 30 µm. (Right) Bar graph shows that ramelteon did not decrease the number of degenerating neurons in the perilesional region of the Nrf2 KO mice. n = 6 mice/group. *P < 0.05 vs. sham group (one-way ANOVA followed by Bonferroni post hoc test).
|
|
| S1204 |
MelatoninMelatonin is a MT receptor agonist, used as a dietary supplement. Melatonin is a selective ATF-6 inhibitor and downregulates COX-2. Melatonin enhances mitophagy and regulates the homeostasis of apoptosis and autophagy. |
TUNEL staining of treated adipocytes and flow cytometry analysis of positive TUNEL cells (n=3). |
|
| S4281 |
TasimelteonTasimelteon (BMS 214778, VEC 162) is a selective dual melatonin receptor (MT1/MT2) agonist with 2.1-4.4 times greater affinity for the MT2 receptor believed to mediate circadian rhythm phase-shifting (Ki = 0.0692 nM and Ki = 0.17 nM in NIH-3T3 and CHOeK1 cells, respectively), than for the MT1 receptor (Ki = 0.304 nM and Ki = 0.35 nM, respectively). |
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S1259 |
RamelteonRamelteon (TAK-375) is a novel melatonin receptor agonist for human MT1 and MT2 receptors and chick forebrain melatonin receptors with Ki of 14 pM, 112 pM and 23.1 pM, respectively. |
(M) (Left) Cresyl violet and Luxol fast blue staining of ipsilateral corpus striatum on day 3 post-TBI. Scale bar = 50 µm. (Right) Bar graph shows that ramelteon did not increase the percentage of area with normal myelin in the Nrf2 KO mouse brain compared with that in the vehicle group. n = 6 mice/group. *P < 0.05 vs. sham group (one-way ANOVA followed by Bonferroni post hoc test). (N) (Left) Fluoro-Jade C staining of the perilesional cerebral cortex on day 3 post-TBI. Scale bar = 30 µm. (Right) Bar graph shows that ramelteon did not decrease the number of degenerating neurons in the perilesional region of the Nrf2 KO mice. n = 6 mice/group. *P < 0.05 vs. sham group (one-way ANOVA followed by Bonferroni post hoc test).
|
|
| S1204 |
MelatoninMelatonin is a MT receptor agonist, used as a dietary supplement. Melatonin is a selective ATF-6 inhibitor and downregulates COX-2. Melatonin enhances mitophagy and regulates the homeostasis of apoptosis and autophagy. |
TUNEL staining of treated adipocytes and flow cytometry analysis of positive TUNEL cells (n=3). |
|
| S4281 |
TasimelteonTasimelteon (BMS 214778, VEC 162) is a selective dual melatonin receptor (MT1/MT2) agonist with 2.1-4.4 times greater affinity for the MT2 receptor believed to mediate circadian rhythm phase-shifting (Ki = 0.0692 nM and Ki = 0.17 nM in NIH-3T3 and CHOeK1 cells, respectively), than for the MT1 receptor (Ki = 0.304 nM and Ki = 0.35 nM, respectively). |
